FibroBiologics

Home
United States
Houston, TX
FibroBiologics

FibroBiologics holds 270+ patents.

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials.

10/29/2026

“We need to stop asking for a stronger immune system. We need to start asking for a smarter one.”

For Pete O’Heeron, Founder and CEO of FibroBiologics, that idea gets to the heart of the research.

A healthy immune system isn’t simply about more activity. It depends on balance, knowing when to respond to a threat and when to stand down.

That’s why FibroBiologics is studying the thymus and fibroblast-based approaches that may help us better understand immune education, regulation, and age-related immune decline.

NASDAQ: FBLG

👉 See the full presentation behind the research: bit.ly/how-immunity-ages

10/28/2026

What if the goal isn’t to push the immune system harder, but to help rebuild the place that teaches it balance?

In FibroBiologics’ preclinical research, thymus organoids produced more than one type of immune cell. Researchers observed regulatory T cells, gamma delta T cells, natural killer cells, and a broad range of receptors associated with diverse immune recognition.

That matters because a healthy immune system needs both defenders and regulators, what Pete describes as “soldiers and peacekeepers.”

Researchers then explored a bold next step in a melanoma mouse model: could immune education be targeted? In that study, mice receiving the melanoma-trained organoid developed significantly smaller tumors, with immune cells present inside the tumors in an activated state.

This research remains preclinical, but it points to a different idea: not simply immunotherapy, but immune education with a target.

NASDAQ: FBLG

👉 See the full presentation behind the research: bit.ly/how-immunity-ages

10/27/2026

Can immune education be targeted?

In preclinical research, FibroBiologics developed a thymus organoid designed around melanoma and studied whether it could help direct the immune system toward a specific target.

In a mouse model, animals that received the organoid developed smaller tumors and showed increased immune-cell activity within the tumors.

The research remains preclinical, but it raises an important question: could rebuilding immune education someday help the body respond more precisely to disease?

NASDAQ: FBLG

👉 See the full presentation behind the research: bit.ly/how-immunity-ages

10/26/2026

For decades, many immune treatments have worked by pushing the immune response in one direction or the other.

When the immune system is overactive, we suppress it. When it’s underactive, we try to stimulate it.
But both extremes can carry trade-offs.

A weak immune response may fail to recognize threats. An overly aggressive response can begin damaging the body it is meant to protect.

That’s why the bigger question isn’t how to create more immunity. It’s how to create smarter, more balanced immunity.

That idea is helping shape the research underway at FibroBiologics.

NASDAQ: FBLG

👉 See the full presentation behind the research: bit.ly/how-immunity-ages

10/22/2026

What is a thymus organoid?

In FibroBiologics’ preclinical research, fibroblasts, thymic epithelial cells, and T cell progenitors are brought together to form a small three-dimensional structure designed to recreate key aspects of the thymic environment.

These organoids are being studied for their ability to support T-cell development and help researchers better understand how thymic function may be restored or supported.

This work is currently in the pre-clinical stage, but it represents an important step in exploring new approaches to immune function, aging, and longevity.

NASDAQ: FBLG

👉 See the full presentation behind the research: bit.ly/how-immunity-ages

10/22/2026

Behind your breastbone sits a small organ with a major role in immune function: the thymus.

The thymus acts as a training center for developing T cells, helping create a diverse population of immune cells capable of recognizing different threats.

But unlike many other organs, thymic function declines with age.

That’s why FibroBiologics is studying the thymus and the role immune education may play in aging, longevity, and immune function.

Your immune system doesn’t just need strength. It needs education.

NASDAQ: FBLG

👉 See the full presentation behind the research: bit.ly/how-immunity-ages

10/20/2026

Why fibroblasts?

Fibroblasts help build and maintain the structural environment throughout our tissues. That role is one reason they are such an important focus of research at FibroBiologics.

Our team is studying whether fibroblasts can help support the cellular environment needed for thymic function and immune development, including through preclinical thymus organoid research.

It starts with a simple question: if fibroblasts help build biological structures, what else could they help make possible?

NASDAQ: FBLG

👉 See the full presentation behind the research: bit.ly/how-immunity-ages

10/19/2026

What happens when a thymus organoid is introduced into the body?

In preclinical animal studies, FibroBiologics researchers observed that the body accepted the organoid, supplied it with blood flow, and the organoid began producing T cells.

Those T cells then traveled through the lymphatic system, supporting further study of how this approach may influence immune function.

It’s an early-stage finding, but it points to a new way of exploring immune longevity and healthy aging through thymus organoid research.

NASDAQ: FBLG

👉 See the full presentation behind the research: bit.ly/how-immunity-ages

10/15/2026

What is “inflammaging”?

It’s the term researchers use to describe the chronic, low-grade inflammation that can develop as we age.

Unlike acute inflammation, inflammaging can persist quietly over time and has been studied in connection with age-related changes in immune function and chronic disease.

At FibroBiologics, understanding how aging affects the immune system is helping shape our preclinical research into thymic function, immune balance, and longevity.

NASDAQ: FBLG

👉 See the full presentation behind the research: bit.ly/how-immunity-ages

10/14/2026

“Stop counting the years in your life. Start fighting for the life in your years.”

That idea captures the bigger goal behind FibroBiologics’ thymus research.

As the thymus declines with age, so does an important part of the body’s ability to educate new immune cells. Instead of focusing only on the downstream effects of that decline, FibroBiologics is exploring whether thymus organoid technology could someday help address the source.

The vision isn’t simply to add more years. It’s to explore ways science may help preserve immune function and support healthier years throughout life.

NASDAQ: FBLG
👉 See the full presentation behind the research: bit.ly/how-immunity-ages

Address

Houston, TX

Website

http://www.FibroBiologics.com/

Alerts

Be the first to know and let us send you an email when FibroBiologics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.